as monotherapy or in combination with Merck’s (MRK) anti-PD-1 therapy, KEYTRUDA, in patients with advanced solid tumors, at the 39th Annual Meeting of the Society for Immunotherapy of Cancer, held in ...

To gather further insights in the intersection of cell therapy and immunology, we welcome articles addressing, but not limited to, the following themes: - Construction of CAR or other engineered T ...

3,4 Despite the requirement of continued therapy to achieve a benefit with golimumab and baricitinib, these interventions modified the course of type 1 diabetes, resulting in reduced insulin need, ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and ...

The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can dramatically improve outcomes for many cancers. But for about 70% of patients, these ...

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T ...